Prostate Cancer Clinical Trial

AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients

Summary

This study is to obtain acute dose safety and pharmacokinetics/pharmacodynamics (PK/PD) data in a dose-response trial in prostate cancer patients.

View Full Description

Full Description

The long-term goal of the study is to conduct human clinical trials to test Angelica gigas Nakai (AGN) root alcoholic extract herbal supplement product (AGN-CognI.Q, or CognI.QTM, made with INM®176 proprietary ingredient, Quality of Life Laboratories, Purchase, NY) as a safe and potential efficacious modality for prostate cancer interception akin to secondary prevention to delay hormonal therapy or avoid it entirely after patients have developed recurrent disease following their standard of care (SOC) surgery and radiation curative treatment. The acute dose safety and pharmacokinetics (PK) and pharmacodynamics (PD) information in the target patient population from the current proposed acute PK dose-response trial will inform the optimal design and execution of the longer-term safety and efficacy (phase I/II) trials.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Willingness and ability to give informed consent.
Agree to comply with all study procedures and attend all study visits to the best of their ability.
Male with age >=40 years.
Histologically confirmed prostate cancer diagnosis in the past. Subjects with history of neuroendocrine or small cell prostate cancer histology will be excluded.
Not on concurrent androgen deprivation therapy.
ECOG performance status 0-2.
Life expectancy of greater than 12 months.

Subjects must have normal liver and kidney function as defined below:

a) total bilirubin within normal institutional limits,
b) AST(SGOT)/ALT(SGPT) < 2.5 X institutional upper limit of normal,
c) Creatinine within 1.5 ULN of institutional limits OR creatinine clearance > 30 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal.
d) Adequate bone marrow function (Hgb ≥ 9.0 g/dL, Platelets ≥ 100 x 109/L, absolute neutrophil count of ≥ 1.5 x 109/L).
Subjects must agree to use two medically accepted method of contraception and must agree to continue use this method while on the trial and through at least one week after the last dose of study drug. Acceptable methods of contraception include abstinence, barrier method with spermicide, intrauterine device (IUD) known to have a failure rate of less than 1% per year, or steroidal contraceptive (oral, transdermal, implanted, or injected) in conjunction with a barrier method. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods) withdrawal, spermicides only, or lactational amenorrhea are not acceptable methods of contraception.
Subjects must stop the CYP3A4 and CYPC19 strong inhibitors or inducers 2 weeks prior to the start of the study and during the study.
Subjects currently taking herbal supplements containing AGN extract, including CognI.Q, Decursinol-50, Ache Action, Fast-Acting Joint Formula, EstroG-100/Profemin must discontinue these or any other supplements continuing these products 4 weeks prior to starting study drug.

Exclusion Criteria:

Subjects with metastatic cancer as determined by chest and abdominal CT scan, PET/CT (conventional FDG or prostate specific imaging such as AXUMIN or PSMA directed PET), MRI, bone scan within the past 12 months. Choice of imaging is per physician's discretion.
Subjects who are receiving chemotherapy, or oral TKI, or immunotherapy (checkpoint inhibitor).
Subjects who are receiving any other investigational agents.
Uncontrolled intercurrent illness that would limit compliance with study requirements.
All vulnerable patient populations.
History of New York Heart Association Class III or IV heart failure, history of a myocardial infarction within 6 months, any uncontrolled cardiac arrhythmia, or any other cardiac related problem that would be considered a contraindication for participation in the opinion of the treating physician.
Use of androgen deprivation therapy (ADT) or anti-androgen therapy including LHRH agonist, antagonist, GNRH analogs, and antiandrogens.

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

12

Study ID:

NCT05375539

Recruitment Status:

Recruiting

Sponsor:

Milton S. Hershey Medical Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Penn State Cancer Institute
Hershey Pennsylvania, 17033, United States More Info
Monika Joshi, MD
Contact
717-531-8678
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

12

Study ID:

NCT05375539

Recruitment Status:

Recruiting

Sponsor:


Milton S. Hershey Medical Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.